Fiche publication
Date publication
juillet 2020
Journal
British journal of cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr COUTANT Charles
,
Dr DABAKUYO-YONLI Sandrine
,
Dr LADOIRE Sylvain
,
Pr QUANTIN Catherine
,
Dr BILLA Oumar
Tous les auteurs :
Simon J, Chaix M, Billa O, Kamga AM, Roignot P, Ladoire S, Coutant C, Arveux P, Quantin C, Dabakuyo-Yonli TS
Lien Pubmed
Résumé
According to international guidelines, endocrine therapy (ET) is the preferred option for hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer. In spite of clear recommendations, these are not strictly followed in daily practice. The objectives of this study were to investigate the effect of the first anti-metastatic treatment therapy choice on progression-free survival (PFS) and overall survival (OS).
Référence
Br. J. Cancer. 2020 Jul 17;:
